Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-05-15
2007-05-15
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S455000
Reexamination Certificate
active
09753892
ABSTRACT:
Methods of treating an individual who has a disease or disorder associated with one or more genetic mutations or undesirable alleles in genomic DNA of the individual, or preventing an individual from developing a disease or disorder associated with one or more genetic mutations or undesirable alleles in genomic DNA of the individual, by replacing a segment of genomic DNA that has a mutated sequence or undesirable allele with a corresponding segment of DNA that has a non-mutated sequence or desirable allele, are disclosed. Methods of inducing tolerance and preventing transplant rejection in a recipient, methods of inducing tolerance and or reducing allergies are disclosed and method of increasing fertility in a woman are disclosed. Each of the methods comprises replacing a segment of genomic DNA in an individual with a corresponding segment of DNA from another. An apparatus for doing large scale PCR preparations is disclosed. Pharmaceutical compositions that comprise a plurality of polynucleotide molecules which collectively comprise an essentially complete genome in polynucleotide molecules having about 100–3000 nucleotides are disclosed.
REFERENCES:
patent: 3803116 (1974-04-01), Sekiguchi et al.
patent: 5176203 (1993-01-01), Larzul
patent: 5302389 (1994-04-01), Kripke et al.
patent: 5352458 (1994-10-01), Yarosh
patent: 5470577 (1995-11-01), Gilchrest et al.
patent: 5589369 (1996-12-01), Seidman et al.
patent: 5792633 (1998-08-01), Schiestl et al.
patent: 5795972 (1998-08-01), Kmiec
patent: 5955059 (1999-09-01), Gilchrest et al.
patent: 5998382 (1999-12-01), Furth et al.
patent: 6010908 (2000-01-01), Gruenert et al.
patent: 6033880 (2000-03-01), Haff et al.
patent: 6093392 (2000-07-01), High et al.
patent: 6093567 (2000-07-01), Gregory et al.
Yáñez et al. “Therapeutic gene targeting,” Gene Ther. 5: 149-159, Feb. 1998.
Riele et al., “Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs,” Proc. Natl. Acad. Sci. USA, 89: 5128-5132, Jun. 1992.
Porter, A.C.G., “Correcting a deficiency,” Mol. Ther. 3 (4): 423-424, 2001.
Ledoux, L., “Uptake of DNA by living cells,” Prog. Nucleic Acid Res. Mol. Biol. 4:231-267, 1965.
Yoon et al., “Bases for failure to induce transformation in vivo with exogenous, homologous DNA in mice, autoradiographic investigation of incorporation of exogenous DNA labeled with 3H-thymidine into germ cells,” Expt. Cell. Res. 34: 599-602, 1964.
Karpfel et al., “Chromosome aberrations produced by deoxyribonucleic acids in mice,” Expt. Cell. Res. 32 : 147-216, 1963.
Wilczok et al., “DNA repair of radiation damage. I. DNA adminstered to rats after whole-body irradiation,” Int. J. Rad. Biol. Rel. Stud. Phys. Chem. Med. 9 (3): 201-211, 1965.
Ledoux et al., “Penetration and fate of exogenous DNA into cells of normal and irradiated mammalian tissues,” U.S. Clearinghouse Fed. Sci. Tech. Inform. No. 715018, 1970.
Taubes, G. “The strange case of chimeraplasty,” Science 298: 2116-2120, Dec. 13, 2002.
Deng et al., “Reexamination of gene targeting frequency as a function of the extent of homologoy between the targeting vector and target locus,” Mol. Cell. Biol. 12 (8): 3365-3371, Aug. 1992.
Bearn et al., “Failure of deoxyribonucleic acid to produce pigment changes in the albino rat,” Exp. Cell. Res. 17 (3): 547-549, Jun. 1959.
Szybalska et al., “Genetics of human cell lines, IV. DNA-mediated heritable transformation of a biochemical trait,” Proc. Natl. Acad Sci. USA 48: 2026-2034, 1962.
Anderson et al., “Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks,” Mutat. Res. 330: 115-181, 1995.
Kawabata et al., “The fate of plasmid DNA after intravenous injection of mice: involvement of scavanger receptors in its hepatic uptake,” Pharm. Res. 12 (6): 825-830, 1995.
Sigma Molecular Biology Catalog, p. 60, 1993.
2000/2001 Sigma Catalog, p. 319, received by PTO on Feb. 15, 2000.
Alexeev, V ., et al., “Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide,”Nature Biotechnology, 1998, 16, 1343-1346.
Baccetti, B., et al., “Apoptosis in human ejaculated sperm cells (notulae seminologicae 9),”J. Submicrosc Cytol Pathol., 1996, 28(4), 587-596,PubMed Query, http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=, 1 page, English abstract.
Bendich, A., et al., “Information transfer and sperm uptake by mammalian somatic cells,”Nucl. Acids Res. M.B., 1976, 17, 43-75.
Bennett, R.M., “As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells,”Antisense Res. And dev., 1993, 3, 235-241.
Billingham, R.E. “Actively acquired tolerance of foreign cells.” Nature 172: 603-606, 1953.
Gershenzon, S.M., “The selectivity of the mutagenic action of DNA and other polynucleotides,”Zh Obshch Biol., 1996, 57(6), 661-683,PubMed, http://www.ncbi.nlm.nih.gov:80/entrez/que...db=PubMed&list—uids=dopt=abstract, 1 page, English abstract.
Gershenson, S.M., “Induction of directed mutations in drosophila melanogaster,”Doklady Akademii Nauk, 1939, vol. XXV(3), 225-227, English abstract.
Gershenson, S.M., “Viruses as environmental mutagenic factors,”Mutation Research, 1986, 203-213.
Guvakova, M.A., et al., “Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix,”J. Biochemical Chem., 1995, 270(6), 2620-2627.
Immunological Tolerance,Chapter 14, 187-198.
Kaledin, V.I., et al., “A new strain of a/he mice hepatoma (hepatoma “A”),”Institute of Cytology and Genetics, 1974, 3 pages, English abstract.
Lederman, S., et al., “Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independently of G-tetrad formation,”Antisense&Nucleic Acid Drug Dev., 1996, 6, 281-289.
Morrison, C., et al., “Extrachromosomal recombination occurs efficiently in cells defective in various DNA repair systems,”Nucleic Acids Res., 1996, 24(11), 2053-2058.
Pfeiffer, P., “The mutagenic potential of DNA double-strand break repair,”Toxicol. Letts., 1998, 96-97, 119-129.
Ridge, J.P., et al., Neonatal tolerance revisited: turning on newborn T cells with dendritic cells,Science, 1996, 271, 1723-1726.
Rykova, E.Y., et al., “Serum immunoglobulins interact with oligonucleotides,”FEBS Lets., 1994, 344, 96-98.
Scott, D.W., “Tollerance,”Encyclopedia of Imm., New York, 1992, 1481-1487.
Simon, A.R., et al., “Efficacy of adhesive interactions in pig-to-human xenotransplantation,”Immunology Today, 1999, 20(7), 323-329.
Telenius, H., et al., “Degenerate oligonucleotide-primed PCR: General amplification of target DNA by a single degenerate primer,”Genomics, 1992, 13, 718-725.
Tonkinson, J.L., et al., “Cellular pharmacology and protein binding of phosphoromonothioate and phosphorodithioate oligodeoxynucleotides: A comparative study,”Antisense Res. And Dev., 1994, 4, 269-278.
Vlassov, V.V., et al., “Penetration of oligonucleotides into mouse organism through mucosa and skin,”FEBS 12763, 1993, 327(3), 271-274.
Vlassov, V.V., et al., “Iontophoretic delivery of oligonucleotide derivatives into mouse tumor,”Antisense Res. And Dev., 1994, 4, 291-293.
Vlassov, V.V., et al., “Transport of oligonucleotides across natural and model membranes,”Biochimica et Biophysica Acta, 1994, 1197, 95-108.
Wagner, T.E., et al., “Human sperm chromatin has a nucleosomal structure,”Arch. Androl., 1981, 7, 251-257.
Yakubov, L.A., et al., “Oli
Panagenic International, Inc.
Pepper Hamilton LLP
Priebe Scott D.
LandOfFree
Compositions comprising genome segments and methods of using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions comprising genome segments and methods of using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions comprising genome segments and methods of using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3741313